Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, p...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Bioinformation
मुख्य लेखकों: Arannilewa1, Abiodun Julius, Suleiman Alakanse, Oluwaseun, Adesola, Adesola Oluwaseun, Israel Malachi, Oluwaseyi, Michael Obaidu, Ifedayo, Oluwafemi, Emmanuel Ekun, Damilola Afolayan, Emmanuel, Folakemi Afere, Patricia, Abdullateef Ayuba, Kayode, Oluwafemi Bolarinwa, Tolulope, Oche Ambrose, George
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Biomedical Informatics 2018
विषय:
Hypothesis
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://ncbi.nlm.nih.gov/pubmed/31223207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6026/97320630014482
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन